<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple myeloma: Overview of management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple myeloma: Overview of management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple myeloma: Overview of management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob P Laubach, MD, MPP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1062479"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple myeloma (MM) is a plasma cell neoplasm characterized by clonal plasma cells that produce a monoclonal immunoglobulin. These plasma cells proliferate in the bone marrow and can result in extensive skeletal destruction with osteolytic lesions, osteopenia, and/or pathologic fractures. Additional disease-related complications include hypercalcemia, kidney impairment, anemia, and infections. </p><p>This topic reviews the overall treatment strategy for patients with MM. Further details regarding the selection of initial therapy, the treatment of relapsed and/or refractory disease, and the use of hematopoietic cell transplantation are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H2044628927"><span class="h1">PRETREATMENT EVALUATION</span></p><p class="headingAnchor" id="H2"><span class="h2">Verify the diagnosis</span><span class="headingEndMark"> — </span>The first step in evaluating a new patient with MM is to verify the diagnosis, since the premalignant stages of myeloma, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), may be easily misdiagnosed as MM if one is not careful. As an example, patients with MGUS may have kidney failure due to diabetes or hypertension, or they may have bone lesions from other cancers. Such patients may be misdiagnosed with MM if these findings are incorrectly attributed to the plasma cell dyscrasia. Therefore, every effort should be made to determine whether the observed "end-organ damage" is truly secondary to the underlying plasma cell disorder or to an unrelated process. </p><p>This distinction is important clinically. All patients with a confirmed diagnosis of MM require treatment; without effective therapy, symptomatic patients die within a median of six months [<a href="#rid1">1</a>]. In contrast, SMM and MGUS may remain stable for prolonged periods and are managed differently. </p><p>Diagnosis of MM is based on criteria from the International Myeloma Working Group  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>) [<a href="#rid2">2</a>]. An approach to the evaluation of suspected cases is presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>) and discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p>The main conditions to consider in the differential diagnosis for MM include MGUS, SMM, Waldenström macroglobulinemia, solitary plasmacytoma, AL amyloidosis, POEMS syndrome, and metastatic carcinoma  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef67431" href="/z/d/graphic/67431.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H55652897"><span class="h2">Clinical evaluation</span><span class="headingEndMark"> — </span>The initial evaluation of patients with MM must establish the extent and sites of disease, the patient's performance status  (<a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">table 4</a>), and comorbid conditions that could complicate overall management. In addition, specific tests are performed for risk stratification and to determine eligibility for autologous hematopoietic cell transplantation (HCT). Particular attention should be paid in the history and physical examination to constitutional symptoms, bone pain, neurologic findings, and infections.</p><p>Our pretreatment evaluation also includes the following studies, some of which are performed as part of the diagnostic evaluation (see  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Evaluation'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A complete blood count and differential with examination of the peripheral blood smear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chemistry screen plus measurements of serum calcium, albumin, lactate dehydrogenase (LDH), and beta-2 microglobulin. (See  <a class="medical medical_review" href="/z/d/html/6658.html" rel="external">"Multiple myeloma: Staging and prognostic studies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine and an estimation of glomerular filtration rate (GFR) [<a href="#rid3">3</a>]. The assessment of GFR and evaluation to determine the cause of kidney impairment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'Assessment of GFR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum free light chain (FLC) assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A serum protein electrophoresis (SPEP) with immunofixation and quantitation of immunoglobulins. A routine urinalysis and a 24-hour urine collection for protein electrophoresis (UPEP) and immunofixation. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow aspiration and biopsy with immunophenotyping and fluorescence in situ hybridization (FISH). FISH should include probes that identify t(11;14), t(4;14), t(6;14), t(14;16), t(14;20), del17p13, gain 1q, and trisomies of odd numbered chromosomes. FISH for del1p32 can provide additional prognostic information, if available. (See  <a class="medical medical_review" href="/z/d/html/6658.html" rel="external">"Multiple myeloma: Staging and prognostic studies", section on 'Other cytogenetic lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cross-sectional imaging (eg, CT, PET/CT, or MRI) for the detection of bone involvement. The choice of imaging modality is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Choice of modality'</a>.)</p><p></p><p>A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the older patient with MM, thus permitting the formulation of an appropriate, individualized treatment plan [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">"Comprehensive geriatric assessment for patients with cancer"</a>.)</p><p class="headingAnchor" id="H55652978"><span class="h2">Risk stratification</span><span class="headingEndMark"> — </span>We risk stratify individual cases based on the results of FISH for specific translocations and certain other tests  (<a class="graphic graphic_table graphicRef78344" href="/z/d/graphic/78344.html" rel="external">table 5</a>). This risk stratification helps to determine prognosis and impacts treatment choice  (<a class="graphic graphic_algorithm graphicRef97453" href="/z/d/graphic/97453.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk myeloma</strong> – We consider patients with at least one of the following clinical or pathologic criteria to have high-risk MM:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(4;14), t(14;16), t(14;20), del17p13, or gain 1q by FISH</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LDH levels ≥2 times the institutional upper limit of normal</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Features of primary plasma cell leukemia (defined as ≥5 percent circulating plasma cells on a manual differential count) (see  <a class="medical medical_review" href="/z/d/html/6646.html" rel="external">"Plasma cell leukemia"</a>)</p><p></p><p class="bulletIndent1">While patients with a high-risk signature on gene expression profiling (GEP) are considered to have high-risk myeloma, this test is not recommended on a routine basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard-risk myeloma</strong> – We consider patients who lack all of the high-risk abnormalities described above to have standard-risk MM. This includes patients with trisomies, t(11;14), and t(6;14).</p><p></p><p>Our risk stratification has evolved over time and will continue to change as our understanding regarding the prognostic value of specific cytogenetic findings in MM improves. While we test for all of the FISH markers described above, some are not available in some regions of the world. The Revised International Staging System, which takes into account the international availability of specific FISH probes, considers patients with any of the following as having high-risk MM: t(4;14), t(14;16), and del17p [<a href="#rid5">5</a>].</p><p>Support for our risk stratification comes from the following (see  <a class="medical medical_review" href="/z/d/html/6658.html" rel="external">"Multiple myeloma: Staging and prognostic studies"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with t(4;14), t(14;16), t(14;20), del17p13, or gain 1q by FISH account for approximately 25 percent of MM and have a shortened median survival with standard treatment [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While deletion 13 and hypodiploidy have been considered adverse prognostic factors when detected by conventional cytogenetics, these are not independent predictors of poor outcome when FISH results are taken into account.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are conflicting data on whether the presence of trisomies can ameliorate some of the adverse prognostic effects of high-risk cytogenetic abnormalities. We do not downgrade our risk assignment for those with trisomies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated LDH is a marker of adverse prognosis in myeloma. Elevated LDH is included in the calculation of the revised International Staging System  (<a class="graphic graphic_table graphicRef132695" href="/z/d/graphic/132695.html" rel="external">table 6</a>) and is used as an inclusion criterion for trials investigating novel therapies for patients with high-risk MM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a high-risk signature on GEP are also considered to have high-risk MM, but this test is not recommended on a routine basis.</p><p></p><p>The underlying genetic abnormalities in the myeloma clone dictate disease biology and are a major predictor of outcome. Prognosis also depends on host factors (age, performance status, comorbidities), stage, and response to therapy. Staging and prognosis is discussed in more detail separately as is the impact of specific cytogenetic findings. (See  <a class="medical medical_review" href="/z/d/html/6658.html" rel="external">"Multiple myeloma: Staging and prognostic studies"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Determine transplant eligibility</span><span class="headingEndMark"> — </span>All patients are assessed to determine eligibility for autologous HCT. HCT eligibility impacts the initial management of patients with MM regardless of whether they choose to proceed with HCT as part of their initial management. Clinicians should have a low threshold to refer patients to a transplant center to discuss candidacy, the role of HCT, and preferred timing. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>General eligibility requirements</strong> – Eligibility for autologous HCT in MM varies across countries and institutions. In most European countries, transplantation for MM is offered primarily to patients younger than 65 years of age. In the United States (US), a strict age limit is not used. Instead, decisions are made on a case-by-case basis based on "physiologic age" and vary across institutions. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1">In most centers in the US, patients with one or more of the following factors are <strong>not</strong> usually considered eligible for autologous HCT in myeloma:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age &gt;77 years</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Frank cirrhosis of the liver</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4 unless due to bone pain  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 7</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New York Heart Association (NYHA) functional status class III or IV  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 8</a>)</p><p></p><p class="bulletIndent1">These are guidelines and the decision on transplant eligibility should be made based on a risk-benefit assessment and the needs and wishes of the patient. </p><p></p><p class="bulletIndent1">In the US, the Centers for Medicare and Medicaid Services approves reimbursement for high-dose therapy with autologous HCT in newly diagnosed patients with MM who are &lt;78 years old and have Durie-Salmon stage II or III disease, and for selected patients who have been previously treated. Additional details are available on the Centers for Medicare and Medicaid Services website at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cms.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlAe98UB2lKjgRrYasPGFDL8%3D&amp;TOPIC_ID=6643" target="_blank">www.cms.gov</a>. Studies that have evaluated the impact of age on transplant efficacy are described in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation", section on 'Age'</a>.)</p><p></p><p class="bulletIndent1">Dose adjustment of the conditioning regimen may be necessary for older adults undergoing HCT. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Older adults'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney function</strong> – Autologous HCT may be safely performed among patients with all stages of kidney disease, even among patients on dialysis. Kidney impairment appears to have no adverse effect on either the quality of stem cell collection or engraftment following autologous HCT [<a href="#rid7">7</a>]. However, patients with kidney impairment can have a more complicated transplant course and increased transplant-related mortality. As such, patients and clinicians must consider the heightened risk associated with the procedure in this population, particularly if the patient has access to effective treatment options at the time of progression.</p><p></p><p class="bulletIndent1">The randomized trials that have shown benefit with HCT compared with chemotherapy have mainly studied patients with serum creatinine &lt;2 mg/dL (177 micromol/L). Patients with higher creatinine levels must be approached with care. The conditioning regimen should use a reduced dose of <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> since toxicity is increased with standard doses in this population. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Patients with kidney impairment'</a>.)</p><p></p><p class="bulletIndent1">Retrospective series suggest that HCT in patients with MM and dialysis-dependent kidney failure is associated with a relatively high transplant-related mortality (15 percent) and greater toxicity than in those without kidney dysfunction [<a href="#rid8">8</a>]. Studies evaluating autologous HCT in patients with MM and kidney impairment are presented separately. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation", section on 'Kidneys'</a>.)</p><p></p><p class="headingAnchor" id="H55640338"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>Patients with MM are not cured with conventional therapy. Treatment alleviates symptoms, reverses cytopenias, and decreases end-organ damage, and it aims to achieve a sustained response, improve quality of life, and prolong overall survival (OS).</p><p class="headingAnchor" id="H55653124"><span class="h2">Eligible for autologous transplant</span></p><p class="headingAnchor" id="H2010704188"><span class="h3">Induction, stem cell collection, and timing of HCT</span><span class="headingEndMark"> — </span>Patients eligible for autologous hematopoietic cell transplantation (HCT) should be referred to a transplant center to discuss candidacy, the role of HCT, and preferred timing. (See <a class="local">'Determine transplant eligibility'</a> above.)</p><p>HCT can be incorporated into the initial therapy (early HCT) or deferred until first relapse (delayed HCT). Timing is individualized taking into account age, risk stratification, response to and tolerability of initial chemotherapy, treatment options at relapse, logistic factors, and patient preference. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Early versus late HCT'</a>.)</p><p>General principles of management include:</p><p class="bulletIndent1"><span class="glyph">●</span>Induction chemotherapy is administered for three to six months (cycles) prior to stem cell collection to reduce the number of tumor cells in the bone marrow and peripheral blood, lessen symptoms, and reverse end-organ damage. </p><p></p><p class="bulletIndent1">The regimen used depends on risk stratification, comorbid conditions, and resources available, and limits exposure to agents that may impair stem cell collection or damage stem cells. There is no single preferred induction regimen and different experts use different regimens. Our preferred approach and data supporting this approach are discussed in more detail separately  (<a class="graphic graphic_algorithm graphicRef97453" href="/z/d/graphic/97453.html" rel="external">algorithm 2</a>) as are alternatives for resource-limited settings  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stem cells are collected regardless of whether the patient plans to proceed directly with HCT or store the stem cells for use at a later time. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Collection of stem cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Following stem cell collection, those who choose to defer HCT continue therapy, usually with the same regimen used for induction, followed by maintenance until relapse. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Maintenance for patients who are ineligible for or defer HCT'</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Benefits of autologous HCT versus chemotherapy alone</span><span class="headingEndMark"> — </span>Autologous HCT remains a key component of myeloma therapy in eligible patients and can be incorporated as part of the initial therapy (early HCT) or delayed until first relapse (delayed HCT). Patients eligible for autologous HCT should be referred to a transplant center to discuss candidacy, the role of HCT, and preferred timing. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Early versus late HCT'</a>.)</p><p>When compared with chemotherapy alone, treatment strategies that incorporate autologous HCT result in:</p><p class="bulletIndent1"><span class="glyph">●</span>Superior progression-free survival (PFS), with an improvement in median PFS &gt;20 months</p><p class="bulletIndent1"><span class="glyph">●</span>Manageable short-term toxicities with a low nonrelapse mortality</p><p class="bulletIndent1"><span class="glyph">●</span>Similar overall rates of second primary malignancies, and an increase in myeloid malignancies (ie, acute myeloid leukemia [AML], myelodysplastic syndrome [MDS])</p><p></p><p>Further details regarding these outcomes come from randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression-free survival</strong> – Autologous HCT delays progression by &gt;20 months. This PFS benefit has been a consistent finding across randomized trials of induction therapy followed by early HCT versus chemotherapy alone, including those trials that incorporated three-drug induction therapy followed by maintenance and allowed for HCT at relapse [<a href="#rid9">9-23</a>].</p><p></p><p class="bulletIndent1">In the largest trial using modern triplet therapy (DETERMINATION), 722 patients received three cycles of induction with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd) followed by stem cell collection and were randomly assigned to an additional five cycles of VRd consolidation versus high-dose <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> plus autologous HCT plus two cycles of VRd consolidation, each followed by lenalidomide maintenance until progression or unacceptable toxicity [<a href="#rid9">9</a>]. At the time of relapse, autologous HCT was recommended but not mandated for those assigned to VRd alone; HCT was performed in 78 of 279 (28 percent) patients relapsing after VRd alone. After a median follow-up of 76 months, incorporation of autologous HCT:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median PFS 68 versus 46 months; hazard ratio [HR] 1.53, 95% CI 1.23-1.91). </p><p></p><p class="bulletIndent2">On subgroup analysis, this benefit was seen among the 132 patients with high-risk myeloma (median PFS 56 versus 17 months; HR 1.99, 95% CI 1.21-3.26) and among the 542 patients with standard-risk myeloma (median PFS 82 versus 53 months; HR 1.38, 95% CI 1.07-1.79). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Did not improve OS (estimated five-year OS 81 versus 79 percent; HR 1.10, 95% CI 0.73-1.65).</p><p></p><p class="bulletIndent1">A similar PFS benefit from autologous HCT was reported in two other large randomized trials that used modern three-drug induction regimens and maintenance therapy (IFM 2009 [<a href="#rid10">10</a>], FORTE [<a href="#rid11">11</a>]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicities</strong> – Autologous HCT is associated with short-term toxicities and has a low nonrelapse mortality (approximately 2 percent). In the DETERMINATION trial, when compared with VRd alone, VRd plus HCT increased grade 3 or higher toxicities overall (94 versus 78 percent), including cytopenias (90 versus 62 percent), infection (18 versus 10 percent), gastrointestinal disorders (19 versus 8 percent), and fatigue (6 versus 3 percent) [<a href="#rid9">9</a>]. There was a temporary decrease in quality of life at the time of HCT followed by a return to baseline and further improvement during maintenance.</p><p></p><p class="bulletIndent1">Second primary malignancies were similar overall (10.7 versus 10.4 percent), although there were more cases of AML/MDS (10 cases with HCT versus none). Deaths due to adverse events were consistent with other modern HCT trials (5 versus 1 death). </p><p></p><p class="bulletIndent1">Another analysis of autologous HCT in 1156 patients with MM reported a one-year nonrelapse mortality of 2 percent (95% CI 1-4 percent) [<a href="#rid24">24</a>]. Approximately 25 percent of patients in this study were alive 15 years after first autologous HCT [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation", section on 'Functional status and comorbid illnesses'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall survival</strong> – The impact of autologous HCT on OS appears to depend at least partially on access to modern induction therapy, maintenance, and effective treatments at relapse. Improved OS with autologous HCT was shown in randomized trials that compared autologous HCT versus chemotherapy alone and did not allow for HCT at the time of relapse [<a href="#rid12">12-16</a>]. Many of these trials used older induction therapies and none used a triplet regimen. Two incorporated <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> into the induction regimen:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one trial, 273 patients received four cycles of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (Rd) followed by stem cell collection and were then randomly assigned to consolidation with <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, lenalidomide (MPR) or with high-dose melphalan plus autologous HCT [<a href="#rid15">15</a>]. At a median follow-up of 51 months, HCT resulted in longer median PFS (43 versus 22 months; HR 0.44; 95% CI 0.32-0.61) and OS (82 versus 65 percent at four years; HR 0.55; 95% CI 0.32-0.93).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a second trial, 256 patients underwent induction with Rd followed by stem cell collection and were randomly assigned to consolidation with Rd plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> or with high-dose <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> plus autologous HCT [<a href="#rid16">16</a>]. After a median follow-up of 52 months, those assigned to chemotherapy without HCT had shorter PFS (median 29 versus 43 months; HR 2.51, 95% CI 1.60-3.94) and OS (73 versus 86 percent at four years; HR 2.40, 95% CI 1.32-4.38).</p><p></p><p class="bulletIndent1">In contrast, an OS benefit has not been seen in trials that used modern three-drug induction with maintenance and provided access to delayed HCT and other effective therapies at the time of relapse (DETERMINATION [<a href="#rid9">9</a>], IFM 2009 [<a href="#rid10">10</a>], FORTE [<a href="#rid11">11</a>]). </p><p></p><p class="headingAnchor" id="H2252074119"><span class="h2">Not eligible for autologous transplant</span><span class="headingEndMark"> — </span>Patients ineligible for or without access to autologous HCT are treated with 8 to 12 months of induction chemotherapy followed by maintenance until progression or unacceptable toxicity. </p><p>The chemotherapy used depends on risk stratification, performance status, comorbid conditions, and resources available. There is no single preferred induction regimen and different experts use different regimens. Our preferred approach and data supporting this approach are discussed in more detail separately  (<a class="graphic graphic_algorithm graphicRef97453" href="/z/d/graphic/97453.html" rel="external">algorithm 2</a>) as are alternatives for resource-limited settings  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6650.html" rel="external">"Multiple myeloma: Management in resource-limited settings"</a>.)</p><p>Experts differ in their approach to maintenance therapy in patients with MM who are not candidates for autologous HCT. Maintenance therapy delays progression but also requires careful monitoring for toxicities that may be associated with long-term therapy. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Maintenance for patients who are ineligible for or defer HCT'</a>.)</p><p class="headingAnchor" id="H55640417"><span class="h1">EVALUATING RESPONSE TO TREATMENT</span></p><p class="headingAnchor" id="H1364418840"><span class="h2">Response criteria and monitoring for relapse</span><span class="headingEndMark"> — </span>Patients are evaluated before each treatment cycle to determine how the disease is responding to therapy (ie, tumor burden) and to assess for potential treatment-related and disease-related complications. Details of this evaluation are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment"</a> and <a class="local">'Prevention and management of complications'</a> below.)</p><p>Briefly, the preferred method for assessing tumor burden in a given patient depends on the results of baseline studies and on the suspected degree of response  (<a class="graphic graphic_table graphicRef111430" href="/z/d/graphic/111430.html" rel="external">table 9A</a>). The International Myeloma Working Group (IMWG) uniform response criteria are the preferred criteria to determine the patient's best response to treatment and to define when a relapse has occurred  (<a class="graphic graphic_table graphicRef55362" href="/z/d/graphic/55362.html" rel="external">table 9B</a>).</p><p>The rationale for monitoring disease response is to modify therapy if needed, adjust doses based on response and toxicity, and to identify transplant candidates with resistant disease. (See <a class="local">'Assess eligibility for transplant'</a> below.)  </p><p>Approximately 7 percent of patients will develop a new monoclonal protein that has an isotype (heavy and/or light chain) distinct from the original clone (eg, IgM MGUS in a patient with IgG MM). This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance", section on 'Secondary MGUS'</a>.)</p><p class="headingAnchor" id="H55654210"><span class="h2">Significance of response to chemotherapy</span><span class="headingEndMark"> — </span>The depth of response has prognostic value in MM. Patients who achieve a minimal residual disease (MRD)-negative state have superior progression-free and overall survival compared with those in whom MRD testing shows residual disease [<a href="#rid26">26</a>]. </p><p>Although depth of response as assessed by MRD status has prognostic value, we need more data on whether better outcomes can be achieved by altering therapy based on the extent of response. Randomized trials are evaluating whether outcomes can be improved by administering additional therapy that incorporates agents to which the patient has not yet been exposed in the setting of MRD-positive disease. At present, we do not recommend that patients responding favorably to a given regimen change treatment with the goal of deepening response to achieve MRD-negative status. MRD assessment is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment", section on 'Minimal residual disease assessment'</a>.)</p><p class="headingAnchor" id="H55640429"><span class="h1">RELAPSED OR REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>Most patients with MM will have an initial response to treatment. However, conventional therapy is not curative, and MM will ultimately relapse. In addition, a minority will have primary refractory disease that does not respond to initial treatment.</p><p class="headingAnchor" id="H417911130"><span class="h2">Indications for therapy</span><span class="headingEndMark"> — </span>Progression is usually identified by a rise in monoclonal (M) protein in the serum or urine or in the serum free light chain ratio  (<a class="graphic graphic_table graphicRef111430 graphicRef55362" href="/z/d/graphic/111430.html" rel="external">table 9A-B</a>) [<a href="#rid27">27</a>]. However, not all patients with progression on laboratory testing need immediate treatment. (See  <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment"</a>.)</p><p>Therapy for relapsed disease is indicated if there is a clinical relapse, extramedullary disease, or a rapid rise in paraproteins [<a href="#rid28">28-30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical relapse – Development of CRAB symptoms (hypercalcemia, renal insufficiency, anemia, or new bone lesions), using the same definitions as for the diagnosis of MM. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extramedullary plasmacytoma – Plasma cell tumors that arise outside of the bone marrow. If extramedullary relapse is suspected clinically, we evaluate the extent of disease with a whole-body combined fluorine-18-labeled fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT). (See <a class="local">'Extramedullary relapse'</a> below and  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid rise in paraproteins – Salvage therapy is clearly indicated if there is a doubling of the M protein over two to three months, with an increase in the absolute levels of M protein of ≥1 g/dL in the serum or of ≥500 mg per 24 hours in the urine, confirmed by two consecutive measurements. (See  <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment", section on 'Measures of tumor burden'</a>.)</p><p></p><p>In contrast, patients without clinical relapse and with a slower rise in paraproteins may choose to defer therapy. In addition, treatment is not indicated for patients that develop oligoclonal reconstitution after autologous transplantation [<a href="#rid30">30,31</a>].</p><p class="headingAnchor" id="H2911189009"><span class="h2">Selection of therapy</span></p><p class="headingAnchor" id="H1994903803"><span class="h3">General principles</span></p><p class="headingAnchor" id="H4198941158"><span class="h4">Identify aggressive disease (risk stratification)</span><span class="headingEndMark"> — </span>The duration of response can be used to identify patients with clinically aggressive disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who relapse less than 12 months from first-line therapy or relapse on full doses of first-line therapy (ie, refractory disease) are considered to have aggressive disease even if evaluation by fluorescence in situ hybridization (FISH) previously classified their disease as standard risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients previously diagnosed with high-risk disease by FISH who relapse more than two years from initial therapy can be considered as having standard-risk disease at the time of relapse in the absence of new additional high-risk cytogenetic abnormalities  (<a class="graphic graphic_table graphicRef78344" href="/z/d/graphic/78344.html" rel="external">table 5</a>).</p><p></p><p>This classification is supported by retrospective studies that have demonstrated inferior survival among patients who relapse less than 12 months after initial therapy [<a href="#rid32">32-34</a>]. As an example, a retrospective analysis of 102 patients with relapsed MM reported that patients who had a time to first progression ≤12 months had a shorter median overall survival (OS) when compared with those who had a time to first progression after 12 months (20 versus 59 months, respectively) [<a href="#rid32">32</a>].</p><p>Patients with aggressive disease at the time of relapse are best treated with a multiagent chemotherapy regimen, preferably in the context of a clinical trial. These are the patients who will be the least likely to respond to conventional therapies and likely require more intensive treatment, which may include prolonged maintenance therapy, multiagent combination therapy, autologous hematopoietic cell transplantation (HCT), or chimeric antigen receptor (CAR)-T cell therapy.</p><p class="headingAnchor" id="H3679219312"><span class="h4">Assess eligibility for clinical trials</span><span class="headingEndMark"> — </span>There is no single standard therapy for relapsed or refractory MM and practice varies widely; as such, we encourage eligible patients to participate in clinical trials. This is especially important for patients with high-risk disease and patients with multiply relapsed disease who have been exposed to most available agents. (See <a class="local">'Investigational agents and accessing clinical trials'</a> below.)</p><p>When a clinical trial is not available or if a patient does not want to participate in a trial, the choice of therapy depends on eligibility for autologous HCT, what agents have been used previously, how the disease responded to this therapy, aggressiveness of the relapse, side effect profiles, and patient comorbidities. Our approach is generally consistent with that proposed by the International Myeloma Working Group [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H535709383"><span class="h4">Assess eligibility for transplant</span><span class="headingEndMark"> — </span>At the time of first relapse, previously transplant-eligible patients are assessed to determine eligibility for autologous HCT if they have not previously undergone autologous HCT. (See <a class="local">'Determine transplant eligibility'</a> above.)</p><p>Autologous HCT can achieve sustained remissions and delay progression. OS rates are similar among patients who undergo HCT as part of their initial therapy and those who delay HCT until the time of first relapse. (See <a class="local">'Benefits of autologous HCT versus chemotherapy alone'</a> above and  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Early versus late HCT'</a>.)</p><p>Our recommendations regarding HCT are consistent with those in a joint consensus statement by the American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, and the International Myeloma Working Group [<a href="#rid36">36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For those patients who are eligible for HCT but did not undergo HCT as part of their initial treatment, we recommend high-dose chemotherapy followed by autologous HCT at time of first relapse. Patients who are initially refractory to induction chemotherapy (primary refractory disease) can achieve a good response to subsequent autologous HCT, and lack of response to initial therapy does not preclude transplantation. Support for the use of autologous HCT in MM and practical details on the performance of autologous HCT are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second autologous HCT is an acceptable option for patients who experienced a durable benefit (at least 24 months) with the first HCT. Retrospective studies suggest that these patients can attain a progression-free survival (PFS) following second HCT of at least nine months [<a href="#rid37">37,38</a>]. The attractiveness of this approach increases for those who experienced longer remissions and had an uncomplicated post-HCT course. However, the decision to proceed with a second HCT in this population is individualized and must take into consideration that there is now an abundance of other effective treatment options for relapsed disease. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Second autologous HCT after relapse'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in whom cryopreserved stem cells are available, the need for bridging chemotherapy prior to autologous HCT for relapsed MM is based on the clinical need and the anticipated delay to arrange for HCT. If patients have symptomatic relapse or a delay to arrange for transplant of more than a few weeks is anticipated, chemotherapy is administered to control the disease. For patients in whom cryopreserved stem cells are not available, a chemotherapy regimen to reduce tumor burden is almost always needed prior to stem cell mobilization and autologous HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allogeneic HCT can be offered to select young patients with high-risk relapsed MM who have a matched donor and are willing to accept a high treatment-related mortality rate and the conflicting data on the efficacy of the intervention. In highly selected patient populations, allogeneic HCT with reduced-intensity conditioning has achieved long-term disease-free survival (DFS) in a subset of patients, although nonrelapse mortality rates can be as high as 25 percent [<a href="#rid39">39-48</a>]. Allogeneic transplant is typically reserved for patients who have received standard regimens. Bridging chemotherapy is usually administered to control disease until allogeneic HCT. Even if allogeneic HCT can be done expeditiously, it is preferable to use chemotherapy to reduce tumor burden prior to proceeding to HCT. </p><p></p><p class="headingAnchor" id="H1458533345"><span class="h4">Extramedullary relapse</span><span class="headingEndMark"> — </span>Patients with extramedullary plasmacytoma, secondary plasma cell leukemia (PCL), or central nervous system (CNS) involvement at the time of relapse require special consideration:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extramedullary plasmacytoma and secondary PCL</strong> – The development of extramedullary disease or secondary PCL is associated with adverse prognosis and is difficult to treat [<a href="#rid49">49-51</a>]. A multicenter retrospective study of 101 patients with secondary PCL reported a median OS of 4.2 months with a one-year OS of 19 percent among patients who received therapy [<a href="#rid49">49</a>]. Response rates were higher among those who underwent autologous HCT and/or received proteasome inhibitors. If the patient is able to tolerate aggressive therapy, we usually offer multidrug regimens (such as VDT-PACE) for one to two cycles to control disease, and then offer standard three-drug regimens used in the treatment of relapsed myeloma [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/6646.html" rel="external">"Plasma cell leukemia", section on 'Induction therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNS relapse</strong> – CNS relapse is rare and is associated with poor prognosis [<a href="#rid53">53,54</a>]. There are no good data on therapy. Most patients are treated with supportive care only, with radiation therapy to sites of localized CNS disease, or occasionally intrathecal chemotherapy regimens used in the treatment of CNS lymphoma. (See  <a class="medical medical_review" href="/z/d/html/89417.html" rel="external">"Secondary central nervous system lymphoma: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H280235357"><span class="h3">First or second relapse</span><span class="headingEndMark"> — </span>There are many approved treatment combinations for patients with relapsed and/or refractory MM. Most patients experience serial relapses over time and will ultimately receive most if not all available agents at some point during their disease course. Accompanying tables provide active drugs by class  (<a class="graphic graphic_table graphicRef121137" href="/z/d/graphic/121137.html" rel="external">table 10</a>), and major toxicities of selected treatment regimens  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 11</a>). </p><p>The choice of therapy for relapsed MM must consider prior therapy, response, and likelihood of the disease being sensitive or refractory to prior agents. In general, refractory disease is defined as progressing on or within 60 days of receiving standard doses of a specific therapy. </p><p>Whether a patient is <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> sensitive or lenalidomide refractory represents an important determinant of second- or third-line therapy, since many of the regimens that have regulatory approval for this indication incorporate lenalidomide. Our approach is therefore structured according to disease status as it relates to sensitivity or refractoriness to lenalidomide  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 4</a>). (See  <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse"</a>.)</p><p class="headingAnchor" id="H1893305020"><span class="h3">Third or later relapse</span><span class="headingEndMark"> — </span>For patients with third or later relapse, our approach depends on whether the disease is refractory to our most active agents in MM, including:  </p><p class="bulletIndent2"><span class="glyph">•</span>An anti-CD38 monoclonal antibody (eg, <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">isatuximab</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">Pomalidomide</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">Carfilzomib</a></p><p></p><p>The term penta-refractory MM is used for MM that is refractory to all five of these agents/classes. </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with non-penta-refractory disease, the choice of regimen is similar to that in first or second relapse, and it is driven by an understanding of drug sensitivity and expected toxicity  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 4</a>). (See  <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to patients with penta-refractory disease is illustrated in the algorithm and described in more detail separately  (<a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">algorithm 5</a>). (See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse"</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">PREVENTION AND MANAGEMENT OF COMPLICATIONS</span><span class="headingEndMark"> — </span>In addition to therapy directed at the malignant clone, the management of most patients with MM includes preventative measures to reduce the incidence of skeletal events, kidney damage, infections, and thrombosis.</p><p>The importance of these complications was highlighted in a study of death within 60 days of diagnosis in patients with myeloma entering onto the United Kingdom's Medical Research Council (MRC) trials [<a href="#rid55">55</a>]. The incidence of early death was 10 percent, with the most common contributors being bacterial infection (50 percent) and kidney failure (28 percent).</p><p class="headingAnchor" id="H1270195720"><span class="h2">Skeletal lesions and bone health</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Osteoclast inhibitors (eg, bisphosphonate therapy or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>) are administered to prevent skeletal events in patients with one or more lesions on skeletal imaging and those with osteopenia  (<a class="graphic graphic_algorithm graphicRef127382" href="/z/d/graphic/127382.html" rel="external">algorithm 6</a>). (See  <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal cord compression</strong> – Spinal cord compression is a clinical emergency and should be suspected in patients with severe back pain, weakness, or paresthesias of the lower extremities, or bladder or bowel dysfunction or incontinence.</p><p></p><p class="bulletIndent1">Prompt diagnosis and immediate treatment are critically important in the preservation of neurologic function in patients with spinal cord compression. In patients with neurologic symptoms directly due to cord compression, radiation therapy is given along with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and up to half of patients have improvement of motor function with radiation therapy (RT) with longer fractionation schedules providing better relief [<a href="#rid56">56</a>]. </p><p></p><p class="bulletIndent1">Systemic therapy with regimens such as <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd) or bortezomib, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, dexamethasone (VRd) work rapidly and can be used instead of radiation in selected patients if there is minimal neurologic deficit. Surgical decompression is necessary only if the neurologic deficit does not improve or if the compression is due to retropulsed bone. Details regarding the treatment of neoplastic spinal cord compression are presented separately. (See  <a class="medical medical_review" href="/z/d/html/2820.html" rel="external">"Treatment and prognosis of neoplastic epidural spinal cord compression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic and impending fractures</strong> – Pathologic fractures or impending fractures of long bones require stabilization. Although the decision to stabilize lytic lesions is made by an orthopedic surgeon and depends in part upon the location of the lesions, a usual rule of thumb is that if there is 50 percent or more destruction of cortical bone thickness, surgical fixation is required. (See  <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">"Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma"</a>.)</p><p></p><p class="bulletIndent1">Vertebral fractures may benefit from kyphoplasty or vertebroplasty. Most pain related to lytic lesions can be controlled with the combination of analgesics and active myeloma chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/132146.html" rel="external">"Management of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma"</a>.)</p><p></p><p class="bulletIndent1">Kyphoplasty and vertebroplasty have been associated with pain relief in prospective trials in patients with myeloma, but they have not been tested in a blinded fashion [<a href="#rid57">57-60</a>]. The choice between procedures depends on the available expertise. Local RT is rarely needed after these procedures except in rare cases in which the patient has myeloma refractory to systemic therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palliative radiation therapy</strong> – Up to 40 percent of patients with myeloma will require RT to control disease at some point in their disease course [<a href="#rid61">61</a>]. Common indications for RT include uncontrolled pain, spinal cord or nerve root compression, impending spinal cord compression, and pathologic fractures or impending fractures [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1">Postsurgical RT after the stabilization of pathologic fractures and impending fractures of long bones can be considered [<a href="#rid62">62</a>]. Extensive radiation in this setting should be avoided because it can reduce bone marrow reserve, compromise future chemotherapy, and may impair stem cell collection for a future autologous stem cell procedure. As such, the full extent of the surgical hardware need not be covered [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">Multiple retrospective series have evaluated various radiation dose fractionation schemes of palliative RT for MM with no clear evidence of a dose-response relationship [<a href="#rid64">64-68</a>]. Doses as low as 10 to 12 Gy in conventional fractionation can achieve effective pain control. In a phase 3 trial comparing 30 Gy in 10 fractions versus 8 Gy in 1 fraction in 101 patients with MM, the two arms had similar rates of pain relief (84.5 versus 74.4 percent, respectively) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">There are limited data on the safety of combining RT with novel agents in myeloma therapy. The approach appears to be generally safe, although there is a trend towards increased hematologic toxicities, especially when RT is combined with proteosome inhibitors. Concurrent RT with proteosome inhibitors should therefore be administered judiciously, especially in patients with limited marrow reserve [<a href="#rid70">70-72</a>].</p><p></p><p class="headingAnchor" id="H2691642120"><span class="h2">Kidney impairment</span><span class="headingEndMark"> — </span>All patients with MM should take measures to minimize kidney damage (eg, avoid nephrotoxins such as aminoglycosides and nonsteroidal anti-inflammatory drugs [NSAIDs] and maintain adequate hydration). Many medications used for myeloma require dose adjustment for kidney impairment (eg, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>). Treatment of kidney impairment is directed at the underlying cause. (See  <a class="medical medical_review" href="/z/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H4116692131"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Prophylactic measures that may minimize infection in patients with MM include yearly influenza vaccines, pneumococcal vaccine at the time of diagnosis, prophylactic antibiotics during the first months of induction chemotherapy, and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> for selected patients who have recurrent, serious infections. (See  <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">"Infections in patients with multiple myeloma"</a> and  <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a>.)</p><p>Patients suspected of having an infection should be treated promptly with empiric antibiotics covering encapsulated bacteria and gram-negative micro-organisms. (See  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p class="headingAnchor" id="H2841420284"><span class="h2">Thromboembolism</span><span class="headingEndMark"> — </span>Patients with MM are at increased risk of having comorbidities known to be risk factors for the development of venous thromboembolism (VTE) in the general population. In addition, treatment with immunomodulatory drugs (eg, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">pomalidomide</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>) has been associated with high rates of VTE. All patients with MM should have an assessment of their VTE risk so that appropriate prophylaxis may be employed  (<a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">algorithm 7</a>). (See  <a class="medical medical_review" href="/z/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p class="headingAnchor" id="H1559513171"><span class="h2">Other complications</span><span class="headingEndMark"> — </span>Patients with MM may also require specific interventions for the management of hypercalcemia, anemia, neuropathy, and, rarely, hyperviscosity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercalcemia</strong> – Patients with hypercalcemia may be asymptomatic or present with anorexia, nausea, vomiting, polyuria, polydipsia, constipation, weakness, confusion, or stupor. Hypercalcemia can also contribute to the development of kidney impairment.</p><p></p><p class="bulletIndent1">In most patients with MM, the diagnosis of hypercalcemia does not require measurement of the ionized calcium. However, if a patient presents with an elevated serum calcium level but no associated symptoms, the ionized calcium should be measured to confirm hypercalcemia prior to the initiation of treatment since rarely the monoclonal protein binds to calcium [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1">The treatment of hypercalcemia depends on the calcium level, the rapidity with which it developed, and the patient's symptoms. Immediate treatment with hydration, glucocorticoids, bisphosphonates, and/or hemodialysis/<a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">calcitonin</a> is indicated for symptomatic patients. (See  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – The treatment of anemia associated with myeloma depends on the severity of the anemia, the presence or absence of symptoms related to anemia, and whether the patient is undergoing active chemotherapy. Patients with significant symptoms should be considered for red blood cell transfusion. Erythropoiesis-stimulating agents are generally reserved for patients receiving chemotherapy with a hemoglobin level of 10 g/dL or less [<a href="#rid28">28,74,75</a>]. (See  <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathy</strong> – Patients with MM can develop peripheral neuropathy related to the disease itself or as a toxicity of treatment (eg, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>). When it occurs, the painful sensory neuropathy can interfere with quality of life and with performance of activities of daily living, and it may require dose modification and/or treatment discontinuation. </p><p></p><p class="bulletIndent1">It is important to monitor closely for development of chemotherapy-related neuropathy and either modify the dose and/or schedule of the responsible agent or switch to a different drug or combination. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Bortezomib'</a> and  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Thalidomide and related agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperviscosity</strong> – Rarely patients with MM develop the hyperviscosity syndrome. This syndrome is characterized by oronasal bleeding, blurred vision, neurologic symptoms, confusion, and heart failure. Serum viscosity measurements do not correlate well with symptoms or the clinical findings. Plasmapheresis promptly relieves the symptoms and should be performed regardless of the viscosity level if the patient is symptomatic [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p></p><p class="headingAnchor" id="H3927437111"><span class="h1">INVESTIGATIONAL AGENTS AND ACCESSING CLINICAL TRIALS</span><span class="headingEndMark"> — </span>Often, there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=6643" target="_blank">www.clinicaltrials.gov</a>).</p><p>Ongoing trials are evaluating traditional agents in new combinations and evaluating newer agents with different mechanisms of action, novel targets, or more refined targets (eg, additional anti-CD38 monoclonal antibodies [<a href="#rid77">77</a>]). </p><p>Examples of novel targets and associated agents include: </p><p class="bulletIndent1"><span class="glyph">●</span>Cereblon (eg, iberdomide [<a href="#rid78">78</a>], mezigdomide [<a href="#rid79">79</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GPRC5D (eg, MCARH109 [<a href="#rid80">80,81</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FcRH5 (eg, cevostamab)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kinesin spindle protein (eg, filanesib [<a href="#rid82">82</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cyclin dependent kinase (eg, dinaciclib [<a href="#rid83">83</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PIM kinase (eg, PIM447 [<a href="#rid84">84</a>])</p><p></p><p>Some studies are evaluating the addition of agents aimed at restoring drug sensitivity. As an example, initial studies suggest that the protease inhibitor <a class="drug drug_general" data-topicid="9685" href="/z/d/drug information/9685.html" rel="external">nelfinavir</a> impairs proteasome activity and may have synergistic effects when combined with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> [<a href="#rid85">85-87</a>]. A multicenter phase 2 trial suggested that the combination of nelfinavir, bortezomib, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> has activity in proteasome inhibitor-refractory MM [<a href="#rid88">88</a>]. Further studies are needed to confirm this finding. As another example, initial studies suggest that gamma-secretase inhibitors may be used to increase BCMA expression prior to anti-BCMA therapy [<a href="#rid89">89</a>].  </p><p>Additional trials are evaluating oncolytic viruses [<a href="#rid90">90,91</a>].</p><p class="headingAnchor" id="H2002389948"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a>.)</p><p class="headingAnchor" id="H986440"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15531.html" rel="external">"Patient education: Multiple myeloma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/688.html" rel="external">"Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/690.html" rel="external">"Patient education: Multiple myeloma treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Verify the diagnosis</strong> – The first step in evaluating a new patient with multiple myeloma (MM) is to verify the diagnosis since the premalignant stages of myeloma, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), may be easily misdiagnosed as MM  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 2</a>). (See <a class="local">'Verify the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">All patients with confirmed MM should initiate treatment promptly. Without effective therapy, symptomatic patients have a life expectancy less than one year. Treatment is not curative; it alleviates symptoms, reverses cytopenias, decreases end-organ damage, and aims to achieve a sustained response, improve quality of life, and prolong overall survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong> – We risk stratify MM based on the results of fluorescence in situ hybridization (FISH) for specific translocations and certain other tests  (<a class="graphic graphic_table graphicRef78344" href="/z/d/graphic/78344.html" rel="external">table 5</a>). This risk stratification has considerable prognostic value and helps guide management  (<a class="graphic graphic_algorithm graphicRef97453" href="/z/d/graphic/97453.html" rel="external">algorithm 2</a>). (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent1">Patients with high-risk MM are encouraged to enroll in a clinical trial investigating novel therapeutic strategies, since they tend to do less well with conventional treatment options. Outside of a clinical trial, data are limited, and experts differ in their approach. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'High-risk myeloma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determine transplant eligibility</strong> – All patients are assessed to determine eligibility for autologous hematopoietic cell transplantation (HCT). Although guidelines are provided, eligibility varies across institutions and should consider the risk-benefit assessment and the needs and wishes of the patient. (See <a class="local">'Determine transplant eligibility'</a> above.)</p><p></p><p class="bulletIndent1">HCT eligibility impacts the initial management of MM regardless of whether the patient plans to proceed with HCT as part of initial management.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HCT eligible</strong> – Patients eligible for autologous HCT should be referred to a transplant center to discuss candidacy, the role of HCT, and preferred timing. Autologous HCT remains a key component of therapy; incorporation of autologous HCT delays progression and has manageable short-term toxicities. (See <a class="local">'Benefits of autologous HCT versus chemotherapy alone'</a> above.)</p><p></p><p class="bulletIndent2">HCT can be incorporated into the initial therapy or deferred until first relapse. Timing is individualized based on age, risk stratification, response to and tolerability of chemotherapy, treatment options at relapse, logistic factors, and patient preference. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Early versus late HCT'</a>.)</p><p></p><p class="bulletIndent2">Induction chemotherapy is administered for three to six months (cycles) prior to stem cell collection to reduce the number of tumor cells in the bone marrow and peripheral blood, lessen symptoms, and reverse end-organ damage. (See <a class="local">'Eligible for autologous transplant'</a> above.)</p><p></p><p class="bulletIndent2">The regimen used depends on risk stratification, comorbid conditions, and resources available, and limits exposure to agents that may impair stem cell collection or damage stem cells. Practice varies, and our preferred approach is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef97453" href="/z/d/graphic/97453.html" rel="external">algorithm 2</a>) as are alternatives for resource-limited settings  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Risk-stratified treatment'</a>.)</p><p></p><p class="bulletIndent2">Stem cells are collected regardless of whether the patient plans to proceed directly with HCT or store the stem cells for use at a later time. Those who choose to defer HCT continue therapy, usually with the same regimen used for induction, followed by maintenance until relapse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HCT ineligible</strong> – Patients ineligible for or without access to autologous HCT are treated with 8 to 12 months of induction chemotherapy followed by maintenance until progression or unacceptable toxicity. (See <a class="local">'Not eligible for autologous transplant'</a> above.)</p><p></p><p class="bulletIndent2">The chemotherapy used depends on risk stratification, performance status, comorbid conditions, and resources available. Practice varies and our preferred approach is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef97453" href="/z/d/graphic/97453.html" rel="external">algorithm 2</a>) as are alternatives for resource-limited settings  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Risk-stratified treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and management of complications</strong> – In addition to therapy directed at the malignant clone, the management of most patients with MM includes preventative measures to reduce the incidence of skeletal events, kidney damage, infections, and thrombosis. Patients with MM may also require specific interventions for the management of hypercalcemia, anemia, and neuropathy. (See <a class="local">'Prevention and management of complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluating response</strong> – Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy  (<a class="graphic graphic_table graphicRef55362" href="/z/d/graphic/55362.html" rel="external">table 9B</a>). Details on how to determine response to therapy are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed or refractory disease</strong> – Relapsed or refractory MM is usually identified on routine surveillance. Treatment is individualized based on prior therapy, response, and likelihood of the disease being sensitive or refractory to prior agents  (<a class="graphic graphic_algorithm graphicRef134483" href="/z/d/graphic/134483.html" rel="external">algorithm 4</a> and <a class="graphic graphic_algorithm graphicRef134484" href="/z/d/graphic/134484.html" rel="external">algorithm 5</a>). (See <a class="local">'Relapsed or refractory disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">OSGOOD EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960; 9:1.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016; 34:1544.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125:2068.</a></li><li><a class="nounderline abstract_t">Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33:2863.</a></li><li><a class="nounderline abstract_t">Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016; 127:2955.</a></li><li><a class="nounderline abstract_t">Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.</a></li><li><a class="nounderline abstract_t">St Bernard R, Chodirker L, Masih-Khan E, et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 2015; 50:95.</a></li><li><a class="nounderline abstract_t">Richardson PG, Jacobus SJ, Weller EA, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 2022; 387:132.</a></li><li><a class="nounderline abstract_t">Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017; 376:1311.</a></li><li><a class="nounderline abstract_t">Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021; 22:1705.</a></li><li><a class="nounderline abstract_t">Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335:91.</a></li><li><a class="nounderline abstract_t">Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104:3052.</a></li><li><a class="nounderline abstract_t">Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371:895.</a></li><li><a class="nounderline abstract_t">Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 2015; 16:1617.</a></li><li><a class="nounderline abstract_t">Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24:929.</a></li><li><a class="nounderline abstract_t">Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101:2144.</a></li><li><a class="nounderline abstract_t">Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23:9227.</a></li><li><a class="nounderline abstract_t">Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106:3755.</a></li><li><a class="nounderline abstract_t">Lévy V, Katsahian S, Fermand JP, et al. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore) 2005; 84:250.</a></li><li><a class="nounderline abstract_t">Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92:3131.</a></li><li><a class="nounderline abstract_t">Dhakal B, Szabo A, Chhabra S, et al. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:343.</a></li><li><a class="nounderline abstract_t">Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014; 20:402.</a></li><li><a class="nounderline abstract_t">Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv 2020; 4:422.</a></li><li><a class="nounderline abstract_t">Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol 2017; 3:28.</a></li><li><a class="nounderline abstract_t">Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17:e328.</a></li><li><a class="nounderline abstract_t">Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014; 32:587.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117:4691.</a></li><li><a class="nounderline abstract_t">Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 2016; 30:1005.</a></li><li><a class="nounderline abstract_t">Tovar N, de Larrea CF, Aróstegui JI, et al. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica 2013; 98:1142.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Falco P, et al. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110:824.</a></li><li><a class="nounderline abstract_t">Helm-Petersen S, Sørrig R, Klausen TW, et al. Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. Leukemia 2018; 32:2054.</a></li><li><a class="nounderline abstract_t">Majithia N, Rajkumar SV, Lacy MQ, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 2016; 30:2208.</a></li><li><a class="nounderline abstract_t">Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol 2021; 22:e105.</a></li><li><a class="nounderline abstract_t">Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 2015; 21:2039.</a></li><li><a class="nounderline abstract_t">Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91:141.</a></li><li><a class="nounderline abstract_t">Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009; 43:417.</a></li><li><a class="nounderline abstract_t">Efebera YA, Qureshi SR, Cole SM, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 2010; 16:1122.</a></li><li><a class="nounderline abstract_t">Patriarca F, Einsele H, Spina F, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant 2012; 18:617.</a></li><li><a class="nounderline abstract_t">de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41:953.</a></li><li><a class="nounderline abstract_t">Shimoni A, Hardan I, Ayuk F, et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer 2010; 116:3621.</a></li><li><a class="nounderline abstract_t">Kröger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010; 148:323.</a></li><li><a class="nounderline abstract_t">Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106:1084.</a></li><li><a class="nounderline abstract_t">Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109:3588.</a></li><li><a class="nounderline abstract_t">Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102:3447.</a></li><li><a class="nounderline abstract_t">Greil C, Engelhardt M, Ihorst G, et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica 2019; 104:370.</a></li><li><a class="nounderline abstract_t">Maffini E, Storer BE, Sandmaier BM, et al. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica 2019; 104:380.</a></li><li><a class="nounderline abstract_t">Jurczyszyn A, Castillo JJ, Avivi I, et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma 2019; 60:118.</a></li><li><a class="nounderline abstract_t">Avivi I, Cohen YC, Suska A, et al. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol 2019; 94:1132.</a></li><li><a class="nounderline abstract_t">Jelinek T, Sevcikova T, Zihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia 2022; 36:288.</a></li><li><a class="nounderline abstract_t">Fernández de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27:780.</a></li><li><a class="nounderline abstract_t">Jun BK, Ho B, Yuen T. Intracranial multiple myeloma with intraparenchymal involvement: Case report and literature review. J Clin Neurosci 2019; 59:335.</a></li><li><a class="nounderline abstract_t">Gozzetti A, Cerase A, Lotti F, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer 2012; 118:1574.</a></li><li><a class="nounderline abstract_t">Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23:9219.</a></li><li><a class="nounderline abstract_t">Rades D, Hoskin PJ, Stalpers LJ, et al. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 2006; 64:1452.</a></li><li><a class="nounderline abstract_t">Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002; 20:2382.</a></li><li><a class="nounderline abstract_t">Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003; 98:21.</a></li><li><a class="nounderline abstract_t">Lane JM, Hong R, Koob J, et al. Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res 2004; :49.</a></li><li><a class="nounderline abstract_t">Hentschel SJ, Burton AW, Fourney DR, et al. Percutaneous vertebroplasty and kyphoplasty performed at a cancer center: refuting proposed contraindications. J Neurosurg Spine 2005; 2:436.</a></li><li><a class="nounderline abstract_t">Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma. Cancer 2005; 103:393.</a></li><li><a class="nounderline abstract_t">Terpos E, Zamagni E, Lentzsch S, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol 2021; 22:e119.</a></li><li><a class="nounderline abstract_t">Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 101:794.</a></li><li><a class="nounderline abstract_t">Leigh BR, Kurtts TA, Mack CF, et al. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993; 25:801.</a></li><li><a class="nounderline abstract_t">Lee JW, Lee JE. Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions. Radiat Oncol J 2016; 34:59.</a></li><li><a class="nounderline abstract_t">Elhammali A, Amini B, Ludmir EB, et al. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 2020; 105:e355.</a></li><li><a class="nounderline abstract_t">Price JG, Niedzwiecki D, Oyekunle T, et al. Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions. Adv Radiat Oncol 2021; 6:100729.</a></li><li><a class="nounderline abstract_t">Meredith RF, Bassler JR, McDonald AM, et al. Biological Effective Radiation Dose for Multiple Myeloma Palliation. Adv Radiat Oncol 2023; 8:101214.</a></li><li><a class="nounderline abstract_t">Rudzianskiene M, Inciura A, Gerbutavicius R, et al. Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study. Strahlenther Onkol 2017; 193:742.</a></li><li><a class="nounderline abstract_t">Shin SM, Chouake RJ, Sanfilippo NJ, et al. Feasibility and efficacy of local radiotherapy with concurrent novel agents in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2014; 14:480.</a></li><li><a class="nounderline abstract_t">Resende Salgado L, Wang S, Adler A, et al. The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era. Adv Radiat Oncol 2019; 4:112.</a></li><li><a class="nounderline abstract_t">Oertel M, Schlusemann T, Shumilov E, et al. Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma-A Critical Toxicity Evaluation in the Modern Treatment Era. Cancers (Basel) 2023; 15.</a></li><li><a class="nounderline abstract_t">Annesley TM, Burritt MF, Kyle RA. Artifactual hypercalcemia in multiple myeloma. Mayo Clin Proc 1982; 57:572.</a></li><li><a class="nounderline abstract_t">Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv 2019; 3:1197.</a></li><li><a class="nounderline abstract_t">Mikhael J, Ismaila N, Cheung MC, et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol 2019; 37:1228.</a></li><li><a class="nounderline abstract_t">Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995; 10:128.</a></li><li><a class="nounderline abstract_t">Kassem S, Diallo BK, El-Murr N, et al. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood 2022; 139:1160.</a></li><li><a class="nounderline abstract_t">Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol 2022; 9:e822.</a></li><li><a class="nounderline abstract_t">Richardson PG, Trudel S, Popat R, et al. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2023; 389:1009.</a></li><li><a class="nounderline abstract_t">Mailankody S, Devlin SM, Landa J, et al. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med 2022; 387:1196.</a></li><li><a class="nounderline abstract_t">Xia J, Li H, Yan Z, et al. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial. J Clin Oncol 2023; 41:2583.</a></li><li><a class="nounderline abstract_t">Ocio EM, Motlló C, Rodríguez-Otero P, et al. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. Br J Haematol 2021; 192:522.</a></li><li><a class="nounderline abstract_t">Gregory GP, Kumar S, Wang D, et al. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Adv 2022; 6:1232.</a></li><li><a class="nounderline abstract_t">Raab MS, Thomas SK, Ocio EM, et al. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia 2019; 33:2924.</a></li><li><a class="nounderline abstract_t">Bono C, Karlin L, Harel S, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica 2012; 97:1101.</a></li><li><a class="nounderline abstract_t">Kawabata S, Gills JJ, Mercado-Matos JR, et al. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis 2012; 3:e353.</a></li><li><a class="nounderline abstract_t">Driessen C, Kraus M, Joerger M, et al. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2016; 101:346.</a></li><li><a class="nounderline abstract_t">Driessen C, Muller R, Novak U, et al. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018.</a></li><li><a class="nounderline abstract_t">Cowan AJ, Pont MJ, Sather BD, et al. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol 2023; 24:811.</a></li><li><a class="nounderline abstract_t">Russell SJ, Federspiel MJ, Peng KW, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89:926.</a></li><li><a class="nounderline abstract_t">Oku M, Ishino R, Uchida S, et al. Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms. Br J Haematol 2021; 192:343.</a></li></ol></div><div id="topicVersionRevision">Topic 6643 Version 69.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13731417" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The survival time of patients with plasmocytic myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439696" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976420" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25628469" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240224" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002115" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11564069" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Results of autologous stem cell transplant in multiple myeloma patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25285800" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35660812" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28379796" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774221" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649495" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12736280" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265788" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184862" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Autologous transplantation and maintenance therapy in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26596670" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16432076" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456509" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275936" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16105975" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010209" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9787148" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29302684" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24342394" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990333" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term outcomes after autologous stem cell transplantation for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27632282" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27511158" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419113" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292775" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26710887" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23645688" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17594696" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29500392" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27211270" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33662288" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26428082" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434386" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The role of second autografts in the management of myeloma at first relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18850013" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20178853" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21820394" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18297115" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564132" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19912215" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16456814" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17158231" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12855572" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30237266" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30262560" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29965787" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31334859" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34247197" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288300" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442452" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Intracranial multiple myeloma with intraparenchymal involvement: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21932386" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275935" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413695" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Short-course radiotherapy is not optimal for spinal cord compression due to myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981012" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12546384" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15346051" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Kyphoplasty enhances function and structural alignment in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871483" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Percutaneous vertebroplasty and kyphoplasty performed at a cancer center: refuting proposed contraindications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15593373" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33545067" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976492" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683017" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Radiation therapy for the palliation of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27104168" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31919088" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34258474" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37124314" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Biological Effective Radiation Dose for Multiple Myeloma Palliation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28573476" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25176474" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Feasibility and efficacy of local radiotherapy with concurrent novel agents in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706018" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37296874" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma-A Critical Toxicity Evaluation in the Modern Treatment Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6810030" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Artifactual hypercalcemia in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30971397" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30932732" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10155178" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hyperviscosity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35201323" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36209764" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37646702" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36170501" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : GPRC5D-Targeted CAR T Cells for Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36881785" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, PhaseⅡTrial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32501528" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34972202" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31092894" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271897" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22825471" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26659919" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37414012" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24835528" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Remission of disseminated cancer after systemic oncolytic virotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33216988" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
